Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Synagis in High-Risk Russian Children
NCT01006629Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Nov 2009
- Primary completion
- Apr 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of palivizumab in respiratory syncytial virus infection (RSV), sponsored by Abbott Laboratories. Started Nov 2009; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT01006629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01006629.